🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Standard of Care PD-1 Therapy

Found 276 matching trials

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

PHASE1

This is a Phase 1/2 study of the combination of Ad-p53 administered intra-a...

Status

Terminated

Location

MD Anderson Cancer Center

Start Date

2018-11-20

Trial ID

NCT02842125

Treatments Being Tested

Ad-P53 Xeloda Keytruda Opdivo

Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy

PHASE3

This is a Phase III, multicenter, open-label, randomized controlled trial. ...

Status

Recruiting

Location

Henan Cancer Hospital

Start Date

2026-06-16

Trial ID

NCT07629817

Treatments Being Tested

Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy Radiation with Concurrent Chemotherapy Radical Esophagectomy

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

PHASE2

The object of this trial is to test whether ivonescimab is superior to stan...

Status

Recruiting

Location

CHU Amiens Picardie

Start Date

2025-10-09

Trial ID

NCT06529718

Treatments Being Tested

Ivonescimab FOLFOX regimen

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

PHASE1

This phase I/II trial investigates the side effects of genetically engineer...

Status

Terminated

Location

Fred Hutch/University of Washington Cancer Consortium

Start Date

2021-07-19

Trial ID

NCT04639245

Treatments Being Tested

Atezolizumab Cyclophosphamide Fludarabine MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells PD1 Inhibitor

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

PHASE3

The purpose of this study is to determine the efficacy and safety of pembro...

Status

Completed

Location

Anhui Provincial Hospital ( Site 0032)

Start Date

2017-04-27

Trial ID

NCT03062358

Treatments Being Tested

pembrolizumab placebo best supportive care (BSC)

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

PHASE3

Researchers are looking for new ways to treat Limited-Stage Small Cell Lung...

Status

Active Not Recruiting

Location

Ironwood Cancer & Research Centers ( Site 0007)

Start Date

2020-12-08

Trial ID

NCT04624204

Treatments Being Tested

Pembrolizumab 200 mg Pembrolizumab 400 mg Pembrolizumab placebo (saline)Pembrolizumab placebo (saline)Olaparib 300 mg BID Olaparib matching placebo Etoposide 100 mg/m^2 Platinum, investigator's choice Standard Thoracic Radiotherapy Prophylactic Cranial Irradiation (PCI)

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

PHASE1

This phase I/II trial studies the side effects of gene-modified immune cell...

Status

Terminated

Location

Fred Hutch/University of Washington Cancer Consortium

Start Date

2019-07-03

Trial ID

NCT03747484

Treatments Being Tested

Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR Avelumab Pembrolizumab Interferon Gamma-1b

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

PHASE1

The purpose of this study is to evaluate the safety and tolerability of an ...

Status

Recruiting

Location

City of Hope

Start Date

2026-06

Trial ID

NCT07484022

Treatments Being Tested

GB-4362 enfortumab vedotin (EV)Pembrolizumab

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

PHASE2

Immunotherapy with immune checkpoint inhibitors, including pembrolizumab, h...

Status

Active Not Recruiting

Location

UPMC Hillman Cancer Center

Start Date

2023-03-30

Trial ID

NCT05467670

Treatments Being Tested

Pembrolizumab ALX148 Doxorubicin

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

N/A

This Observational study will explore the utility of the Biodesix, Inc. "PI...

Status

Terminated

Location

Addario Lung Cancer Medical Institute (ALCMI)

Start Date

2021-02-01

Trial ID

NCT04676386

Treatments Being Tested

Primary Immune Response (PIR) test by Biodesix, Inc.

Previous Next